Nanodecal's cutting-edge technology is revolutionizing the way we diagnose respiratory diseases to make possible a new paradigm in precision therapy. Our innovative solutions offer new methods for obtaining, treating, and analyzing respiratory samples with user-friendly devices that can be easily integrated into any healthcare setting. This breakthrough technology has the potential to significantly improve patient outcomes and streamline the diagnostic process.
Our cutting-edge technology detects the superbug Pseudomonas aerunginosa in minutes. This speed and precision at the point of care fullfills an unmet need in respiratory medicine.
Our technology provides accurate and timely information, enabling healthcare professionals to make informed decisions for the treatment of respiratory conditions more effectively.
Respiratory samples can be thick, making it difficult to analyze them quickly. Nanodecal addresses this challenge by using a unique method to liquefy these samples instantly. Traditional rapid tests may have limited sensitivity due to detecting only one bacterial antigen. Nanodecal's innovative nanosensors can identify whole cells, enhancing the test's accuracy. To get quantitative results from our tests, all you need is a smartphone and our free app for reading the results. This approach combines our expertise in rapid tests and computer vision to deliver an accurate and user-friendly experience.
At Nanodecal, our rapid test is made possible by combining three breakthrough technologies pioneered in our lab.
The scientific foundation of our patented technology is build on our published work in high quality, peer-reviewed journals.
We are putting together a multidisciplinary team to bring Nanodecal's breakthrough biotech to market. Together, we will make a significant impact in the field of respiratory diagnostic tools.
Roberto de la RicaCEO | CSO | Founder
I am committed to help Nanodecal grow so that our technology can help patients. I am thrilled by the idea of guiding therapeutic decisions using scientific evidence obtained on the spot.
Joins our team with the with the enthusiasm of bringing a new medical device to the market.
Steven M. RussellRegulatory Affairs Manager
I develop and maintain the quality management and risk management systems needed to inform decisions with real-world evidence. I am excited to be managing regulatory affairs to support the growth of Nanodecal.
Cristina AdroverR&D | Founder
I'm a passionate R&D specialist and company founder, devoted to advancing healthcare through developing cutting-edge biosensor technology.
Andreu VaquerR&D | Founder
I am a founder of Nanodecal and dedicated to shaping the future through groundbreaking research, pioneering new frontiers in nanoparticle-based IVDs.
David Delgado-CanoProduction & Operations | R&D
Brings the know-how for biosensor manufacturing during a 1-year stay at our lab. Skills: Biosensor development, validation studies
Antonio ClementeR&D | Founder
Miguel Servet Researcher at Multidisciplinary Sepsis Group
President of the Code Sepsis Foundation and Director of the Sepsis Area at FEPIMCTI
Fernando de Marcos
International Senior Executive and Fundraising Consultant
Coordinator of the National Strategy on COPD for the Balearic Islands
Head of Clinical Microbiology at HUSE and world expert in Pseudomonas infections
Regulatory Affairs Manager for Clinical Research and IP Strategy Consultant
Our knowledge of existing medical needs and techonogical solutions is underpinned by our patents and peer-reviewed publications
Sensor Manufacturing Patent
Process for storing and releasing protein-decorated nanoparticles on paper substrates
Sample Treatment Patent
Method for liquifying a respiratory sample and for the subsequent detection of respiratory infections in said sample
RaPId Article 1
Nanoparticle Reservoirs for Paper-Only Immunosensors ACS Sensors 2020